BR112022008571A2 - Composto de azabenzimidazol e medicamento - Google Patents
Composto de azabenzimidazol e medicamentoInfo
- Publication number
- BR112022008571A2 BR112022008571A2 BR112022008571A BR112022008571A BR112022008571A2 BR 112022008571 A2 BR112022008571 A2 BR 112022008571A2 BR 112022008571 A BR112022008571 A BR 112022008571A BR 112022008571 A BR112022008571 A BR 112022008571A BR 112022008571 A2 BR112022008571 A2 BR 112022008571A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- present
- bladder
- underactive
- azabenzimidazole
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019205344 | 2019-11-13 | ||
| PCT/JP2020/042247 WO2021095801A1 (ja) | 2019-11-13 | 2020-11-12 | アザベンゾイミダゾール化合物及び医薬 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022008571A2 true BR112022008571A2 (pt) | 2022-08-09 |
Family
ID=75912665
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022008571A BR112022008571A2 (pt) | 2019-11-13 | 2020-11-12 | Composto de azabenzimidazol e medicamento |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12528813B2 (https=) |
| EP (1) | EP4059933A4 (https=) |
| JP (1) | JP7627661B2 (https=) |
| KR (1) | KR102951288B1 (https=) |
| CN (1) | CN114929697A (https=) |
| AU (1) | AU2020384041A1 (https=) |
| BR (1) | BR112022008571A2 (https=) |
| CA (1) | CA3161582A1 (https=) |
| MX (1) | MX2022005649A (https=) |
| TW (1) | TW202128689A (https=) |
| WO (1) | WO2021095801A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2992256T3 (es) | 2018-05-08 | 2024-12-11 | Nippon Shinyaku Co Ltd | Compuestos de azabencimidazol y producto farmacéutico |
| BR112022008571A2 (pt) * | 2019-11-13 | 2022-08-09 | Nippon Shinyaku Co Ltd | Composto de azabenzimidazol e medicamento |
| US20250092008A1 (en) | 2021-08-10 | 2025-03-20 | Ono Pharmaceutical Co., Ltd. | Process for making an ep4 antagonist |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5571819A (en) | 1994-11-22 | 1996-11-05 | Sabb; Annmarie L. | Imidazopyridines as muscarinic agents |
| NO2005012I1 (no) | 1994-12-28 | 2005-06-06 | Debio Rech Pharma Sa | Triptorelin og farmasoytisk akseptable salter derav |
| US6541669B1 (en) | 1998-06-08 | 2003-04-01 | Theravance, Inc. | β2-adrenergic receptor agonists |
| UA73543C2 (uk) | 1999-12-07 | 2005-08-15 | Тераванс, Інк. | Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором |
| JP2007523957A (ja) | 2004-02-25 | 2007-08-23 | スミスクライン・ビーチャム・コーポレイション | 新規化学化合物 |
| TW200538095A (en) | 2004-03-11 | 2005-12-01 | Theravance Inc | Biphenyl compounds useful as muscarinic receptor antagonists |
| EP1723142A1 (en) | 2004-03-11 | 2006-11-22 | Theravance, Inc. | Diphenylmethyl compounds useful as muscarinic receptor antagonists |
| EP1734820A4 (en) | 2004-04-16 | 2008-01-23 | Neurogen Corp | Imidazopyrrazine, imidazopyridine, and imidazo-pyrimidine as CRF1 receptor ligands |
| EP1928437A2 (en) | 2005-08-26 | 2008-06-11 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| ES2274712B1 (es) | 2005-10-06 | 2008-03-01 | Laboratorios Almirall S.A. | Nuevos derivados imidazopiridina. |
| PT2054405E (pt) | 2006-07-11 | 2013-12-24 | Dae Woong Pharma | Novos derivados de biaril benzoimidazol e composição farmacêutica que compreende os mesmos |
| US8008307B2 (en) | 2006-08-08 | 2011-08-30 | Millennium Pharmaceuticals, Inc. | Heteroaryl compounds useful as inhibitors of E1 activating enzymes |
| GB0706168D0 (en) | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
| MX2010007587A (es) | 2008-01-24 | 2010-08-04 | Ucb Pharma Sa | Compuestos que comprenden un grupo ciclobutoxi. |
| EP2810951B1 (en) | 2008-06-04 | 2017-03-15 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| US8110578B2 (en) | 2008-10-27 | 2012-02-07 | Signal Pharmaceuticals, Llc | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway |
| WO2010130392A1 (de) | 2009-05-11 | 2010-11-18 | Ratiopharm Gmbh | Desfesoterodin in form eines weinsäuresalzes |
| WO2011018894A1 (en) | 2009-08-10 | 2011-02-17 | Raqualia Pharma Inc. | Pyrrolopyrimidine derivatives as potassium channel modulators |
| JP5667934B2 (ja) | 2010-06-28 | 2015-02-12 | 大日本住友製薬株式会社 | 新規２環性複素環化合物からなる医薬 |
| TWI541243B (zh) | 2010-09-10 | 2016-07-11 | 拜耳知識產權公司 | 經取代咪唑并嗒 |
| JP2013545779A (ja) | 2010-12-17 | 2013-12-26 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 過剰増殖性障害の治療におけるｍｐｓ−１およびｔｋｋ阻害剤として使用するための６置換イミダゾピラジン |
| CA2821834A1 (en) | 2010-12-17 | 2012-06-21 | Bayer Intellectual Property Gmbh | 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
| JP6038150B2 (ja) | 2011-08-24 | 2016-12-07 | ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | Ｎｅｄｄ８活性化酵素阻害剤 |
| JP2013237634A (ja) | 2012-05-14 | 2013-11-28 | Dainippon Sumitomo Pharma Co Ltd | 縮環イミダゾロン誘導体 |
| CA2893622A1 (en) | 2012-12-05 | 2014-06-12 | Chiesi Farmaceutici S.P.A. | Novel compounds |
| CN105121439A (zh) | 2013-02-19 | 2015-12-02 | 辉瑞公司 | 作为pde4亚型抑制剂用于治疗cns和其他病症的氮杂苯并咪唑化合物 |
| GB201302927D0 (en) | 2013-02-20 | 2013-04-03 | Cancer Therapeutics Crc Pty Ltd | Compounds |
| TWI647227B (zh) | 2013-02-28 | 2019-01-11 | 日商安斯泰來製藥股份有限公司 | ２－醯胺噻唑衍生物或其鹽 |
| US9326976B2 (en) | 2014-06-05 | 2016-05-03 | Chiesi Farmaceutici S.P.A. | Carbamate derivatives |
| EA031866B1 (ru) | 2014-06-06 | 2019-03-29 | Астеллас Фарма Инк. | Производное 2-ациламинотиазола или его соль |
| BR112017003901A2 (pt) | 2014-08-26 | 2017-12-12 | Astellas Pharma Inc | derivado de 2-aminotiazola ou sal do mesmo |
| ES2907622T3 (es) | 2014-10-06 | 2022-04-25 | Merck Patent Gmbh | Compuestos de heteroarilo como inhibidores de BTK y usos de estos |
| JP6680297B2 (ja) | 2015-04-28 | 2020-04-15 | アステラス製薬株式会社 | 経口投与用医薬組成物 |
| WO2018112840A1 (en) | 2016-12-22 | 2018-06-28 | Merck Sharp & Dohme Corp. | 6, 5-fused heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor |
| CN115504986B (zh) | 2017-03-03 | 2024-05-14 | 江苏豪森药业集团有限公司 | 凋亡信号调节激酶抑制剂及其制备方法和应用 |
| CA3085745A1 (en) | 2017-12-21 | 2019-06-27 | Kyorin Pharmaceutical Co., Ltd. | An agent for treating nocturnal pollakiuria |
| WO2019189766A1 (ja) | 2018-03-30 | 2019-10-03 | 持田製薬株式会社 | 新規ビアリールアミド誘導体 |
| ES2992256T3 (es) | 2018-05-08 | 2024-12-11 | Nippon Shinyaku Co Ltd | Compuestos de azabencimidazol y producto farmacéutico |
| TW202012415A (zh) | 2018-05-08 | 2020-04-01 | 瑞典商阿斯特捷利康公司 | 化學化合物 |
| TWI721623B (zh) | 2018-10-31 | 2021-03-11 | 美商基利科學股份有限公司 | 經取代之6-氮雜苯并咪唑化合物 |
| BR112022008571A2 (pt) * | 2019-11-13 | 2022-08-09 | Nippon Shinyaku Co Ltd | Composto de azabenzimidazol e medicamento |
| WO2021095805A1 (ja) | 2019-11-13 | 2021-05-20 | 日本新薬株式会社 | 機能性消化管障害及び口腔乾燥症の治療剤及び予防剤 |
-
2020
- 2020-11-12 BR BR112022008571A patent/BR112022008571A2/pt unknown
- 2020-11-12 KR KR1020227019556A patent/KR102951288B1/ko active Active
- 2020-11-12 CA CA3161582A patent/CA3161582A1/en active Pending
- 2020-11-12 CN CN202080092956.2A patent/CN114929697A/zh active Pending
- 2020-11-12 AU AU2020384041A patent/AU2020384041A1/en active Pending
- 2020-11-12 EP EP20886259.9A patent/EP4059933A4/en active Pending
- 2020-11-12 MX MX2022005649A patent/MX2022005649A/es unknown
- 2020-11-12 WO PCT/JP2020/042247 patent/WO2021095801A1/ja not_active Ceased
- 2020-11-12 US US17/775,418 patent/US12528813B2/en active Active
- 2020-11-12 JP JP2021556143A patent/JP7627661B2/ja active Active
- 2020-11-13 TW TW109139704A patent/TW202128689A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4059933A1 (en) | 2022-09-21 |
| EP4059933A4 (en) | 2023-11-15 |
| CN114929697A (zh) | 2022-08-19 |
| KR20220100627A (ko) | 2022-07-15 |
| CA3161582A1 (en) | 2021-05-20 |
| US12528813B2 (en) | 2026-01-20 |
| WO2021095801A1 (ja) | 2021-05-20 |
| TW202128689A (zh) | 2021-08-01 |
| JPWO2021095801A1 (https=) | 2021-05-20 |
| MX2022005649A (es) | 2022-06-22 |
| US20230002395A1 (en) | 2023-01-05 |
| KR102951288B1 (ko) | 2026-04-13 |
| JP7627661B2 (ja) | 2025-02-06 |
| AU2020384041A1 (en) | 2022-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022008571A2 (pt) | Composto de azabenzimidazol e medicamento | |
| BR112022010254A2 (pt) | Composto heterocíclico contendo oxigênio representado pela fórmula i, método para preparar o composto heterocíclico contendo oxigênio, composto, composição farmacêutica e uso composto heterocíclico contendo oxigênio | |
| BR112012031580A2 (pt) | derivado de tetra-hidrocarbolina | |
| BR112013002182B8 (pt) | Compostos derivados de quinolina, composição farmacêutica, inibidor de melk, agente modulador de expressão de melk, agente antitumor, agente terapêutico e/ou preventivo para uma doença que envolve a superexpressão de melk contendo os mesmos e uso dos referidos compostos | |
| BR112016024472A2 (pt) | composto, medicamento, métodos para modulação alostérica positiva e para profilaxia ou tratamento de doenças, e, uso de um composto | |
| BR112015019720A2 (pt) | inibidores de (benzil-ciano-metil)-amidas de ácido 2-aza-biciclo[2.2.1]heptano-3-carboxílico substituído da catepsina c | |
| BR112015020302A2 (pt) | derivado de pirazol | |
| BR112022024120A2 (pt) | Derivado de piridina-pirimidina, método de preparação do mesmo e uso farmacêutico do mesmo | |
| BR112015029512A8 (pt) | derivados de pirazolopirrolidina, seus usos, e composição e combinação farmacêuticas | |
| BR112012030177A2 (pt) | composto, uso do mesmo, e, composição farmacêutica | |
| BR112015023922A2 (pt) | composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes | |
| BR112014026493A2 (pt) | derivados de imidazotiadiazol como inibidores do receptor ativado por protease 4 (par4) para tratar a agregação de plaqueta | |
| BR112014025564A2 (pt) | composto heterocíclico contendo nitrogênio ou sal do mesmo | |
| BR112022014889A2 (pt) | Composto de sulfonamida ou sulfinamida possuindo efeito de indução de degradação da proteína brd4 e uso farmacêutico do mesmo | |
| PH12020551873A1 (en) | Azabenzimidazole compounds and pharmaceutical | |
| BR112013007380A2 (pt) | regime de administração para nitrocatecóis | |
| BR112012004851B8 (pt) | uso de um derivado de tiazol | |
| BR112012018765A2 (pt) | agente profilático ou terapêutico para as doenças do trato biliar | |
| BR112019003710A2 (pt) | inibidor de pde7, composto, composição farmacêutica, uso de um inibidor de pde7 ou de um composto, e, método para tratar ou prevenir uma doença que é melhorada pela inibição de pde7. | |
| BR112015026967A8 (pt) | fenoxietil di-hidro-1h-isoquinolina, seus usos, e composição farmacêutica | |
| BR112021018815A2 (pt) | Gepotidacina para uso no tratamento de infecções bacterianas do trato urinário | |
| CL2016001707A1 (es) | Tratamiento de trastornos congnitivos con (r)-7-cloro-n-(quinuclidin-3-il) benzo(b)tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma (div. sol. 1178-11). | |
| BR112023019657A2 (pt) | Antagonista de abhd6 | |
| BR112012022944A2 (pt) | agente terapêutico ou agente profilático | |
| BR112022019486A2 (pt) | Agente terapêutico para infecção por coronavírus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |